Lu sur :https://www.ncbi.nlm.nih.gov/pubmed/29742795
Traduction disponible directement en cliquant en bas à droite de ce message sur l'expression Traduire en
Rituximab in refractory myasthenia gravis: extended prospective study results.
Beecher G1, Anderson D1, Siddiqi ZA1.
Muscle Nerve. 2018 May 9. doi: 10.1002/mus.26156. [Epub ahead of print]
Rituximab appears beneficial in treatment-refractory myasthenia gravis (MG), however, prospective, long-term durability data is lacking.
In this prospective, open-label study of rituximab in refractory MG, 22 patients (10 AChR, 9 MuSK, 3 seronegative) received rituximab at baseline, with repeat cycles driven by clinical worsening. Manual muscle testing (MMT) scores and CD19/CD20+ B cell counts were serially monitored.
At mean follow-up of 28.8 ± 19.0 months (range=6-66 months), mean MMT scores declined from 10.6 ± 5.4 to 3.3 ± 3.1 (p<0.0001). Mean prednisone dose declined from 25.2 ± 15.1 mg/d to 7.3 ± 7.1 mg/d (p=0.002). Ten relapses occurred, with average time to first relapse of 17.1 ± 5.5 months (range=9-23 months). CD19/CD20+ count recovery did not predict relapse. Three patients experienced prolonged B cell depletion (range=24-45 months) after one cycle.
Sustained clinical improvement was associated with rituximab after one cycle, with prolonged time to relapse and reduction in steroid dose.